Susquehanna International Group, LLP Mustang Bio, Inc. Transaction History

Susquehanna International Group, LLP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	BUY	$0.35 - $0.72 $7,739 - $15,921	22,113 Added 131.29%	38,956 $14,000
Q4 2022 Feb 14, 2023	BUY	$0.32 - $8.27 $5,389 - $139,291	16,843 New	16,843 $6,000
Q2 2022 Aug 15, 2022	BUY	$0.58 - $1.13 $68,867 - $134,172	118,737 Added 748.19%	134,607 $79,000
Q1 2022 May 16, 2022	SELL	$0.73 - $1.81 $43,042 - $106,721	-58,962 Reduced 78.79%	15,870 $16,000
Q4 2021 Feb 14, 2022	SELL	$1.66 - $2.64 $25,954 - $41,276	-15,635 Reduced 17.28%	74,832 $124,000
Q3 2021 Nov 15, 2021	SELL	$2.58 - $3.36 $143,675 - $187,111	-55,688 Reduced 38.1%	90,467 $243,000
Q2 2021 Aug 11, 2021	BUY	$2.7 - $3.81 $185,139 - $261,251	68,570 Added 88.38%	146,155 $486,000
Q1 2021 May 17, 2021	BUY	$3.02 - $5.16 $146,273 - $249,924	48,435 Added 166.16%	77,585 $258,000
Q4 2020 Feb 16, 2021	SELL	$2.66 - $4.18 $273,307 - $429,482	-102,747 Reduced 77.9%	29,150 $110,000
Q3 2020 Nov 16, 2020	BUY	$3.01 - $3.88 $205,197 - $264,507	68,172 Added 106.98%	131,897 $415,000
Q2 2020 Aug 14, 2020	BUY	$2.33 - $4.6 $51,385 - $101,448	22,054 Added 52.92%	63,725 $203,000
Q1 2020 May 15, 2020	BUY	$1.91 - $4.52 $55,957 - $132,422	29,297 Added 236.76%	41,671 $112,000
Q3 2019 Nov 14, 2019	BUY	$2.74 - $4.65 $4,658 - $7,905	1,700 Added 15.93%	12,374 $40,000
Q2 2019 Aug 16, 2019	BUY	$2.66 - $6.28 $28,392 - $67,032	10,674 New	10,674 $39,000
Q2 2018 Aug 14, 2018	SELL	$6.68 - $11.0 $526,778 - $867,449	-78,859 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$10.14 - $12.38 $799,630 - $976,274	78,859 New	78,859 $863,000

415K

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $20M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.